Alembic Pharma Shares Gain 2% on USFDA Tentative Approval
Shares of Alembic Pharmaceuticals witnessed a positive move, gaining 2%, on 14 May after the company secured tentative approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Darolutamide Tablets, 300 mg. The approval marks another important step in the company’s expanding presence in the oncology and specialty…